List of Figures
Figure 1: Emerging Pharmaceutical Market: South Africa, Market Forecast ($bn), 2011–2018
Figure 2: Emerging Pharmaceutical Market: South Africa, Market Forecast, 2007–2018
Figure 3: Emerging Pharmaceutical Market: South Africa, Top 10 Causes of Death (%), 2008
Figure 4: Emerging Pharmaceutical Market: South Africa, Causes of Death due to Infectious Diseases (%), 2008
Figure 5: Emerging Pharmaceutical Market: South Africa, HIV/AIDS Population (million), 2001–2011
Figure 6: Emerging Pharmaceutical Market: South Africa, Deaths due to AIDS, 2001–2011
Figure 7: Emerging Pharmaceutical Market: South Africa, Transmission of HIV/AIDS, (%), 2011
Figure 8: Emerging Pharmaceutical Market: South Africa, Tuberculosis Population, 2001–2011
Figure 9: Emerging Pharmaceutical Market: South Africa, Patented vs. Generic Drugs, by Value, 2011
Figure 10: Emerging Pharmaceutical Market: South Africa, Patented vs. Generic Drugs Market Share %, by Volume, 2011
Figure 11: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Imports, 2007–2018
Figure 12: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports, 2007–2018
Figure 13: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports and Imports, 2007–2018
Figure 14: Emerging Pharmaceutical Market: South Africa, Aspen Pharmacare, SWOT Analysis, 2011
Figure 15: Emerging Pharmaceutical Market: South Africa, Adcock Ingram, SWOT Analysis, 2011
Figure 16: Emerging Pharmaceutical Market: South Africa, Cipla Medpro, SWOT Analysis, 2011
Figure 17: Emerging Pharmaceutical Market: South Africa, Sanofi, SWOT Analysis, 2011
Figure 18: Emerging Pharmaceutical Market: South Africa, Pfizer, SWOT Analysis, 2011
Figure 19: Emerging Pharmaceutical Market: South Africa, Roche, SWOT Analysis, 2011
Figure 20: Emerging Pharmaceutical Market: South Africa, Ranbaxy, SWOT Analysis, 2011
Figure 21: Emerging Pharmaceutical Market: South Africa, GlaxoSmithKline, SWOT Analysis, 2011
Figure 22: Emerging Pharmaceutical Market: South Africa, Merck and Co., SWOT Analysis, 2011
Figure 23: Emerging Pharmaceutical Market: South Africa, Novartis, SWOT Analysis, 2011
Figure 24: Emerging Pharmaceutical Market: South Africa, Market Drivers, 2011
Figure 25: Emerging Pharmaceutical Market: South Africa, Market Restraints, 2011
Figure 26: Emerging Pharmaceutical Market: South Africa, PESTLE Analysis, 2011
Figure 27: Emerging Pharmaceutical Market: South Africa, Population of BRICS Nations, 2010
Figure 28: Emerging Pharmaceutical Market: South Africa, Population Structure, (million), 2000–2025
Figure 29: Emerging Pharmaceutical Market: South Africa, Life Expectancy at Birth, 1950–2010
Figure 30: Emerging Pharmaceutical Market: South Africa, Infant Mortality Rate, 2001–2011
Figure 31: Emerging Pharmaceutical Market: South Africa, Rural/Urban Distribution of Population, 1990–2009
Figure 32: Emerging Pharmaceutical Market: South Africa, National Healthcare Expenditure, 2008
Figure 33: Emerging Pharmaceutical Market: South Africa, Private Healthcare Expenditure (%), 2010
Figure 34: Emerging Pharmaceutical Market: South Africa, Increase in Government Healthcare Expenditure over the Previous Year (%), 2011
Figure 35: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Physicians per 10,000 Population, 2010
Figure 36: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Nursing and Midwifery Personnel per 10,000 Population, 2010
Figure 37: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Dentistry Personnel per 10,000 Population, 2010
Figure 38: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Pharmaceutical Personnel per 10,000 Population, 2010
Figure 39: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Hospital Beds per 10,000 Population, 2009
Figure 40: Emerging Pharmaceutical Market: South Africa, Number of Clinical Trials, 2007–2011
Figure 41: Emerging Pharmaceutical Market: South Africa, Strategic Consolidation, Deals by Type, (%), 2009–2011
Figure 42: Emerging Pharmaceutical Market: South Africa, Strategic Consolidations, Deals by Year, 2009–2011
Figure 43: Emerging Pharmaceutical Market: South Africa, M&A Deals by Year, 2009–2011
Figure 44: Emerging Pharmaceutical Market: South Africa, M&A Deals by Type, (%), 2009–2011
Figure 45: Emerging Pharmaceutical Market: South Africa, M&A Deals by Value, %, 2009–2011
Figure 46: Emerging Pharmaceutical Market: South Africa, Quintiles, Company Profile, 2011
Figure 47: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Product Development, Company Profile, 2011
Figure 48: Emerging Pharmaceutical Market: South Africa, Inc Research, Company Profile, 2011
Figure 49: Emerging Pharmaceutical Market: South Africa, Parexel, Company Profile, 2011
Figure 50: Emerging Pharmaceutical Market: South Africa, Icon plc, Company Profile, 2011
Figure 51: Emerging Pharmaceutical Market: South Africa, PRA International, Company Profile, 2011
Figure 52: Emerging Pharmaceutical Market: South Africa, African Clinical Research Organization, Company Profile, 2011
Figure 53: Emerging Pharmaceutical Market: South Africa, OnQ, Company Profile, 2011